



Partner with us as an investigator to tackle the challenge of IBD through science and innovation

If you are interested in becoming a
Lilly investigator, please email:
Become_an_IBD_Investigator@lilly.com



Visit the Lilly booth to find out more!



INTERESTED IN BECOMING A LILLY INVESTIGATOR?

MIRIKIZUMAB (LY3074828)

An immunoglobulin monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23)

PHASE 3 **Ulcerative Colitis (UC)**

**LUCENT 1
AMAN**
NCT03518086

**LUCENT 2
AMBG**
NCT03524092

**LUCENT 3
AMAP**
NCT03519945

**LUCENT-ACT
AMBI**
NCT04469062

PHASE 3 **Crohn's Disease (CD)**

**VIVID-1*
AMAM**
NCT03926130

**VIVID-2
AMAX**
NCT04232553

Pediatric UC/CD

PHASE 3 ***VIVID-1
ADOLESCENT
ADDENDUM
AMAM**
NCT03926130

PHASE 2 **SHINE-1
AMBU**
NCT04004611

Mirikizumab has been granted Orphan Drug Designation from the US FDA for the investigation of ulcerative colitis and Crohn's disease in pediatric patients

The safety and efficacy of the agent under investigation has not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for the uses being investigated.

Mirikizumab is currently in clinical development for ulcerative colitis and Crohn's disease. Efficacy and safety have not yet been established, and its commercial authorization has not been granted by the health authorities. The information provided here is for scientific purposes only. Information available on: <https://clinicaltrials.gov/> and the EU Clinical Trial Register site.

<https://www.accessdata.fda.gov/scripts/opdlisting/ocpd/detailedIndex.cfm?cfgridkey=584617> (Accessed February 2020).
<https://www.accessdata.fda.gov/scripts/opdlisting/ocpd/detailedIndex.cfm?cfgridkey=577817> (Accessed February 2020).

<https://clinicaltrials.gov> (Accessed September 2020).
Tsai YC, Tsai TF. *Ther Adv Musculoskelet Dis*. 2017;9:277-294.

VV-Centralized Congress-US-DEL-0207 September 2020. © 2020 Eli Lilly and Company. All rights reserved.